In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

Benjamin A. Brakel; Chirayu R. Chokshi; Sabra K. Salim; Chitra Venugopal; Sheila Singh

STAR Protocols (Dec 2021)

In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

Benjamin A. Brakel,
Chirayu R. Chokshi,
Sabra K. Salim,
Chitra Venugopal,
Sheila Singh

Affiliations

Benjamin A. Brakel: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada
Chirayu R. Chokshi: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada
Sabra K. Salim: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada
Chitra Venugopal: Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada
Sheila Singh: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada; Corresponding author

Journal volume & issue: Vol. 2, no. 4
p. 100920

Abstract

Read online

Summary: Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies in vitro is needed. This protocol details the in vitro preclinical evaluation of CAR-T cell therapies for glioblastoma (GBM), including target cell cytotoxicity and T cell proliferation, activation, and cytokine release assays.For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

Published in STAR Protocols

ISSN: 2666-1667 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Science (General)
Website: https://star-protocols.cell.com/

About the journal

Abstract

Keywords